Dr. Eric Berg DC · 2026-06-26 · Eric Berg (host), Steve, Tashia, Edward, Amy

The Dr. Berg Show LIVE - June 26, 2026

39 research-tied claims examined: 2 contradicted 10 overstated 3 context 16 supported 8 unverified

Contradicted by research

0:53:33 Eric Berg (host)contradictedhigh

Estrogen replacement therapy that is not paired with progesterone increases the risk of stroke and heart attack.

"There is data that shows uh and I've read this that um like estrogen replacement therapy um that's not paired with progesterone could increase your risk of stroke and heart attack." (said at 0:53:33)

Progestogen is added to estrogen therapy exclusively to prevent endometrial hyperplasia and uterine cancer in women with an intact uterus, not to mitigate cardiovascular risks. Large randomized controlled trial evidence from the Women's Health Initiative (WHI) shows that oral estrogen-alone therapy does increase the risk of ischemic stroke (similar to combined therapy), but it does not increase the risk of coronary heart disease or heart attack (hazard ratio 0.94, 95% CI 0.78–1.14). In fact, adding a progestin (combined hormone therapy) was associated with an early elevation in coronary heart disease risk, rather than offering protection against heart attacks.

contradicts: Menopausal hormone therapy and health outcomes during the intervention and extended postst… (JAMA 2013) · cited 1633x in the literature
"The risks and benefits were more balanced during the CEE alone intervention with 204 CHD cases for CEE alone vs 222 cases for placebo (HR, 0.94; 95% CI, 0.78-1.14) and 104 vs 135, respectively, for invasive breast cancer (HR, 0.79; 95% CI, 0.61-1.02)" (abstract, results, passage verified)
pubmed full study (doi)
context: Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and… (Seminars in reproductive medicine 2014) · cited 37x in the literature
"Specifically, with combined estrogen plus progestin, CHD risk was elevated early with the elevation dissipating after a few years of treatment... Stroke effects, on the contrary, did not seem to vary appreciably with these timing issues. The adverse effect was evidently localized to ischemic strokes, for which there was an approximate 50% increase with either regimen." (abstract)
pubmed full study (doi)

1:01:13 Eric Berg (host)contradictedhigh

Cyanocobalamin does not break down or become active in individuals with methylation issues, resulting in toxic buildup in the body.

"the type they put it in or the type that they have is called cyanocobalamin and that's the one that um is not good for you because it doesn't it has to go through these processes to break down and become active. And so it if you have also a problem with that methylation thing, it it never really breaks down. So you you create a buildup in the body, it becomes toxic." (said at 1:01:13)

The host's claim that cyanocobalamin requires methylation to break down—and that methylation defects prevent its breakdown, causing toxic accumulation—is contradicted by established biochemical literature. Cobalamin (vitamin B12) serves as a coenzyme in human physiology for two primary reactions: the conversion of L-methylmalonyl-CoA to succinyl-CoA and the methylation of homocysteine to methionine (PMID: 39376196). Methylation defects, such as methylene tetrahydrofolate reductase (MTHFR) deficiency, impair folate-dependent remethylation pathways, but they are distinct from cobalamin processing and intracellular trafficking and do not prevent cyanocobalamin breakdown or cause it to build up toxically in the body (PMID: 30761552).

contradicts: The clinical presentation of cobalamin-related disorders: From acquired deficiencies to in… (Journal of inherited metabolic disease 2019) · cited 76x in the literature
"This review gives an overview of clinical characteristics, treatment and outcome of nutritional and acquired cobalamin (Cbl; synonym: vitamin B12) deficiencies, inborn errors of Cbl absorption and intracellular trafficking, as well as methylenetetrahydrofolate dehydrogenase (MTHFD1) and methylene tetrahydrofolate reductase (MTHFR) deficiencies, which impair Cbl-dependent remethylation." (abstract, passage verified)
pubmed full study (doi)
contradicts: Biological properties of vitamin B 12 . (Nutrition research reviews 2025) · cited 26x in the literature
"Vitamin B 12 , cobalamin, is indispensable for humans owing to its participation in two biochemical reactions: the conversion of l-methylmalonyl coenzyme A to succinyl coenzyme A, and the formation of methionine by methylation of homocysteine." (abstract, passage verified)
pubmed full study (doi)

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.